Eisai Resubmits Supplemental New Drug Application for Aricept, Alzheimers Disease Drug, to FDA.Tokyo, Japan, Dec 21, 2005 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Eisai has announced that its US subsidiary Eisai Medical Research resubmitted a supplemental new drug application (sNDA) for Aricept, the company's proprietary agent for treating severe Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. , to the US Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) as of December 16. The US subsidiary first submitted the sNDA on August 31, but the FDA turned down the application on the grounds that the application did not conform to Verb 1. conform to - satisfy a condition or restriction; "Does this paper meet the requirements for the degree?" fit, meet coordinate - be co-ordinated; "These activities coordinate well" the FDA standard. The resubmitted sNDA is expected to be accepted by the FDA within 60 days. Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion